Literature DB >> 12738232

Differential accumulation of non-transferrin-bound iron by cardiac myocytes and fibroblasts.

Ying Liu1, Joel G Parkes, Douglas M Templeton.   

Abstract

Cardiac myocytes accumulate iron preferentially over fibroblast-like non-myocytes, both in clinical iron overload and when the cells are grown together in culture. In order to determine whether this reflects the tissue context or is an inherent property of the cells, we studied iron transporters, transport kinetics, and iron efflux in homogeneous cultures of rat cardiac myocytes and fibroblasts. In both cells, the rate of uptake of 59Fe from transferrin was insignificant, compared to the rate of uptake from non-transferrin-bound iron (NTBI). Expression of transferrin receptor mRNA and protein, and divalent metal transporter 1 (DMT1) mRNA, could not account for any difference in iron accumulation, and proportional efflux after iron loading was similar in both cells. Nevertheless, iron accumulation from NTBI over 72 h was greater in myocytes as determined by histological staining and quantitative iron measurement. NTBI uptake was greater for Fe2+ than Fe3+ in both cells, was increased by iron loading in both cells to a similar extent, and was characterized bysimilar Michaelis constants (K(m)) in all cases (redox state and presence or absence of iron loading). However, V(max) values were about 10-fold higher in myocytes. We conclude that preferential iron accumulation in cardiac myocytes, compared to fibroblasts, is due to a higher capacity of the NTBI-transporter system, and reflects an inherent difference in NTBI acquisition by the individual cell types.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12738232     DOI: 10.1016/s0022-2828(03)00072-5

Source DB:  PubMed          Journal:  J Mol Cell Cardiol        ISSN: 0022-2828            Impact factor:   5.000


  9 in total

1.  Cardiomyocyte ultrastructural damage in β-thalassaemic mice.

Authors:  Chanita Sanyear; Punnee Butthep; Ramaneeya Nithipongvanich; Pornpan Sirankapracha; Pranee Winichagoon; Suthat Fucharoen; Saovaros Svasti
Journal:  Int J Exp Pathol       Date:  2013-10       Impact factor: 1.925

2.  Iron-loaded cardiac myocytes stimulate cardiac myofibroblast DNA synthesis.

Authors:  Ying Liu; Douglas M Templeton
Journal:  Mol Cell Biochem       Date:  2006-01       Impact factor: 3.396

Review 3.  Physiology and pathophysiology of iron cardiomyopathy in thalassemia.

Authors:  John C Wood; Cathleen Enriquez; Nilesh Ghugre; Maya Otto-Duessel; Michelle Aguilar; Marvin D Nelson; Rex Moats; Thomas D Coates
Journal:  Ann N Y Acad Sci       Date:  2005       Impact factor: 5.691

4.  The Steap proteins are metalloreductases.

Authors:  Robert S Ohgami; Dean R Campagna; Alice McDonald; Mark D Fleming
Journal:  Blood       Date:  2006-04-11       Impact factor: 22.113

Review 5.  The Role of Ferroptosis in Adverse Left Ventricular Remodeling Following Acute Myocardial Infarction.

Authors:  Kyoko Komai; Nicholas K Kawasaki; Jason K Higa; Takashi Matsui
Journal:  Cells       Date:  2022-04-20       Impact factor: 7.666

6.  Iron accumulation and iron-regulatory protein activity in human hepatoma (HepG2) cells.

Authors:  Zvezdana Popovic; Douglas M Templeton
Journal:  Mol Cell Biochem       Date:  2004-10       Impact factor: 3.396

7.  Residual erythropoiesis protects against myocardial hemosiderosis in transfusion-dependent thalassemia by lowering labile plasma iron via transient generation of apotransferrin.

Authors:  Maciej W Garbowski; Patricia Evans; Evangelia Vlachodimitropoulou; Robert Hider; John B Porter
Journal:  Haematologica       Date:  2017-06-22       Impact factor: 9.941

Review 8.  Role of L-type Ca2+ channels in iron transport and iron-overload cardiomyopathy.

Authors:  Gavin Y Oudit; Maria G Trivieri; Neelam Khaper; Peter P Liu; Peter H Backx
Journal:  J Mol Med (Berl)       Date:  2006-04-08       Impact factor: 4.599

Review 9.  The (Bio)Chemistry of Non-Transferrin-Bound Iron.

Authors:  André M N Silva; Maria Rangel
Journal:  Molecules       Date:  2022-03-09       Impact factor: 4.411

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.